Pre-Emptive Granulocyte Transfusions (GTX) in Pediatric Patients with a Chronic Bacterial or Fungal Infection Undergoing a Hematopoietic Stem Cell Transplantation (HSCT).

Raphael F. Sharon, H. Vrielink, M. B. Bierings, A. B. Versluijs, J. J. Boelens

Author address: 

Pediatric Hematology, Wilhelmina Children's Hospital, Utrecht, Netherlands; Sanquin Blood Bank Northwest Region, Amsterdam, Netherlands; Pediatric Immunology, Wilhelmina Children's Hospital, Utrecht, Netherlands

Abstract: 

GTX in patients with severe infections and neutropenia have been previously reported to be a therapeutic modality in these group of patients. Patients undergoing HSCT are at risk of developing infections post-transplantation: bacterial and fungal infections mainly during aplasia, and viral reactivation mainly after aplasia. A chronic dormant bacterial or fungal infection prior to the HSCT is a severe risk factor for reactivation, development of acute GvHD and mortality. Pre-emptive GTX could probably influence the susceptibility for reactivation and therefore influence the outcome of the HSCT. We here report our experience with pre-emptive GTX in patients with a chronic dormant bacterial or fungal infection undergoing HSCT. Between 12/2003 and 11/2004, 3 patients (table 1) were treated with pre-emptive GTX prior to HSCT, with a frequency of 3 times a week. From day +7 patients received G-CSF (10 µg/kg). Granulocyte donors (all family donors, age 16-70 years) were screened for CMV (and other viruses), ABO-compatibility and physical condition. They were all asked to sign an informed consent. Preferably ABO-compatible and CMV-negative donors were used where the patient was also CMV negative. In case of ABO-incompatibility anti-A/B was used with a titre 8804; 1:64, except for cases where no other donors were available. Donors were treated with 480 µg G-CSF and 7.5 mg dexamethasone on the evening prior to the apheresis. The target amount of cells harvested was 5*1010/m2 Patient 1 and 3 received respectively a full-graft identical sibling, and a full-graft C-locus mismatched UD, both after myeloablative conditioning. Patient 2 received an identical unrelated donor after reduced intensity conditioning (after unsuccessful first HSCT with poor autologous recovery). All 3 cases underwent the HSCT successfully with a 100% donor chimerism with a follow-up of 8,12 and 18 mth respectively. No flare of the present chronic infection was seen. Although one of the patients had acute GvHD grade 3 (pt 2), no other complications were seen. In addition, no transfusion-related complications were seen. We collected a median of 6.8 * 1010 /m2 (range 2.8-11) granulocytes per transfusion.With this dose, granulocytes were almost continuously present, except in patient 3. Even in patient 1, who only had ABO-incompatible donors with high iso-haemaglutinine levels, no hemolysis or transfusion-related reactions were seen. It is our firm belief that the outcome of these HSCTs was positively influenced by the GTX. Pre-emptive GTX in patients with dormant, chronic infections prior to HSCT is a feasable, low-toxic method to enable HSCT in these patients. A prospective study is needed to investigate the success of pre-emptive use of GTX and whether the complications are indeed minimal in a large group of patients.
2005

abstract No: 

5340

Full conference title: 

47th American Society for Haematology
    • ASH 47th (2005)